Trial Profile
Phase 1b Open-label Study of MK-8353 in Combination With Selumetinib (MK-5618) in Participants With Advanced/Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Apr 2023
Price :
$35
*
At a glance
- Drugs MK 8353 (Primary) ; Selumetinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 11 Apr 2023 Results published in the Investigational New Drugs
- 24 Mar 2021 Status changed from active, no longer recruiting to completed.
- 10 Mar 2021 Planned End Date changed from 23 Sep 2021 to 19 Mar 2021.